Clinical observation of oxaliplatin combined with S-1 on the patients with advanced breast cancer

Objective To evaluate the efficacy and toxicity of the combination of oxaliplatin and S-1 in the treatment of patients with advanced breast cancer. Methods A total of 72 patients with advanced breast cancer after the treatment failuer of anthracycline and taxane were treated with oxaliplatin and S-1. The first day, they were given oxaliplatin, 135 mg/m2, with the 5% glucose injection 500 ml, the time of intravenous drip should be more than 2 hours. And the S-1 was taken after breakfast and dinner, the dose was 40-60 mg, and the time of duration was 2 weeks, then they had 7 days to rest. The cycle was 21 days. Every 2 cycles, we estimated the efficacy. Patients who were effective and stable kept that chemotherapy regimens, the maximum duration was 6 cycles. The efficacy and toxicities were evaluated after cycles of chemotherapy. Results Two cases (2.8%) had complete response (CR), 26 cases (36.1%) had partial response (PR). The response rate (RR) was 38.9% and the disease control rate (DCR) was 69.4%. The median progress free survival (PFS) was 7.7 months and the median overall survival (OS) was 12.3 months. Subgroup analysis showed that the OS of patients who belong to stage Ⅳ, had two or more metastases or with failure treatment after being treated with anthracycline and taxane was notably shorter than the patients who belong to stage ⅢC, only one metastasis, with effective treatment after being treated with anthracycline and taxane, and the differences were statistically significant (10.5 months vs. 15.0 months, χ2=4.469, P=0.035; 9.3 months vs. 15.0 months, χ2=8.297, P=0.004; 10.0 months vs. 14.0 months, χ2=4.077, P=0.043). The main side effects were neutropenia (19.4%), nausea (8.3%) and nerve toxicity (2.8%), mainly 3-4 degree, and could be well-tolerated. The others were diarrhea, impaired liver function, stomatitis, anemia and hand-foot syndrome, mainly 1-2 degree. Conclusion Oxaliplatin combined with S-1 is effective and tolerable in treatment of patients with advanced breast cancer, the adverse reactions can be tolerated. Key words: Breast neoplasms; Neoplasms metastasis; Drug therapy